SCN10A

Chr 3

sodium voltage-gated channel alpha subunit 10

Also known as: FEPS2, Nav1.8, PN3, SNS

The protein encoded by this gene is a tetrodotoxin-resistant voltage-gated sodium channel alpha subunit. The properties of the channel formed by the encoded transmembrane protein can be altered by interaction with different beta subunits. This protein may be involved in the onset of pain associated with peripheral neuropathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2014]

ResearchGenerating clinical summary…
MultiplemechanismLOEUF 1.01
Clinical SummarySCN10A
🧬
Gene-Disease Validity (ClinGen)
Brugada syndrome · ADDisputed

Disputed — evidence questions this relationship

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
1 unique Pathogenic / Likely Pathogenic· 382 VUS of 706 total submissions
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
1.01LOEUF
pLI 0.000
Z-score 1.44
OE 0.82 (0.671.01)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?
-0.68Z-score
OE missense 1.06 (1.011.11)
1144 obs / 1080.9 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?
LoF OE?0.82 (0.671.01)
00.351.4
Missense OE?1.06 (1.011.11)
00.61.4
Synonymous OE?1.12
01.21.6
LoF obs/exp: 65 / 78.8Missense obs/exp: 1144 / 1080.9Syn Z: -1.93
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
limitedSCN10A-related Brugada syndromeOTHERAD

This gene — mechanism propensity

DN
0.7227th %ile
GOF
0.80top 10%
LOF
0.2871th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median · 1 literature citation
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFGain-of-function mutations in the voltage-gated sodium channels SCN9A, SCN10A and SCN11A have been identified as an underlying genetic cause in a subpopulation of patients with SFN.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

References

  1. 1.PMID 30316835

ClinVar Variant Classifications

706 submitted variants in ClinVar

Classification Summary

Likely Pathogenic1
VUS382
Likely Benign257
Benign33
Conflicting31
1
Likely Pathogenic
382
VUS
257
Likely Benign
33
Benign
31
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
0
0
0
Likely Pathogenic
0
1
0
0
1
VUS
30
332
15
5
382
Likely Benign
0
17
91
149
257
Benign
0
0
31
2
33
Conflicting
31
Total30350137156704

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

6 pathogenic / likely-pathogenic (of 11) ClinVar copy-number / structural variants overlap SCN10A — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

SCN10A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →